AOE rates of the respective nonimatinib TKI in the major clinical trials
| . | 2-y report . | 5-y report . | 10-y report . |
|---|---|---|---|
| PACE (ponatinib) | 17.1%3 | 25%7 | Trial ended at 5 y |
| DASISION (dasatinib) | None reported14 | 5%17 | Trial ended at 5 y |
| ENESTnd (nilotinib) | 2% (not including peripheral arterial events)15 | 10.6% (300 mg) 17.9% (400 mg)18,∗ | 24.8% (300 mg) 33.4% (400 mg)18,∗ |
| BELA (bosutinib) | None reported16 | N/A | N/A |
| BFORE (bosutinib) | N/A | 7.5%19 | Trial ended at 5 y |
| ASCEMBL (asciminib) | 5.1% (2.3 y median follow-up)20 | N/A | N/A |
| Imatinib | 1 ischemic heart event in 288 patients (ENESTnd)15 | 2%-2.5%7,17,21 (except in BFORE: 0.4%)19 | 3.6% (400 mg, ENESTnd)18 |
| . | 2-y report . | 5-y report . | 10-y report . |
|---|---|---|---|
| PACE (ponatinib) | 17.1%3 | 25%7 | Trial ended at 5 y |
| DASISION (dasatinib) | None reported14 | 5%17 | Trial ended at 5 y |
| ENESTnd (nilotinib) | 2% (not including peripheral arterial events)15 | 10.6% (300 mg) 17.9% (400 mg)18,∗ | 24.8% (300 mg) 33.4% (400 mg)18,∗ |
| BELA (bosutinib) | None reported16 | N/A | N/A |
| BFORE (bosutinib) | N/A | 7.5%19 | Trial ended at 5 y |
| ASCEMBL (asciminib) | 5.1% (2.3 y median follow-up)20 | N/A | N/A |
| Imatinib | 1 ischemic heart event in 288 patients (ENESTnd)15 | 2%-2.5%7,17,21 (except in BFORE: 0.4%)19 | 3.6% (400 mg, ENESTnd)18 |
Imatinib cardiovascular event rates (bottom row) represent a summary of the rates in the DASISION, ENESTnd, BELA, and BFORE trials.
Kaplan-Meier estimates.